cariprazine

Known as: trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N',N'-dimethylurea hydrochloride 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND Although predominant negative symptoms of schizophrenia can be severe enough to cause persistent impairment, effective… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2016
2016
This 6-week, double-blind, placebo-controlled, proof-of-concept study evaluated the efficacy, safety, and tolerability of low… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2016
2016
BACKGROUND Cariprazine is an atypical antipsychotic currently under investigation as adjunctive therapy in patients with major… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2015
2015
This phase III study evaluated the efficacy and safety of cariprazine, a dopamine D3 and D2 receptor partial agonist with… (More)
Is this relevant?
2015
2015
Cariprazine (Vraylar™) is an oral atypical antipsychotic originated by Gedeon Richter. It is a potent dopamine D3 and D2 receptor… (More)
Is this relevant?
2014
2014
The aim of this study was to evaluate whether chronic treatment with cariprazine, a dopamine D2 and D3 receptor partial agonist… (More)
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
Review
2013
Review
2013
Cariprazine is a dopamine D3-preferring D3/D2 receptor partial agonist in late-stage clinical development for the treatment of… (More)
Is this relevant?
2012
2012
A major challenge in the pharmacological treatment of psychotic disorders is the effective management of the associated cognitive… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Medicinal chemistry optimization of an impurity isolated during the scale-up synthesis of a pyridylsulfonamide type dopamine D(3… (More)
Is this relevant?
Review
2011
Review
2011
We conducted meta-analyses of findings from randomized, placebo-controlled, short-term trials for acute mania in manic or mixed… (More)
Is this relevant?